Overview
- ENDO 2026 presenters reported on Saturday that a retrospective analysis of Fitbit-linked NIH All of Us records found adults with obesity took fewer steps and spent less time in moderate-to-vigorous activity after beginning GLP‑1 drugs.
- The wearable study of 753 participants found average daily steps fell from 5,047 to 4,487 and moderate-to-vigorous activity dropped from about 28 to 22 minutes per day.
- Men and people reporting musculoskeletal joint or muscle pain showed the largest declines in both steps and active minutes, suggesting some subgroups face higher risk of functional loss.
- A separate Komodo Health claims analysis presented at the meeting showed about 4 in 10 patients stopped GLP‑1 therapy within a year and roughly 41.5% of those who stopped restarted within a year, with cost, side effects and payer type associated with discontinuation.
- Study authors and commentators urged that clinicians prescribe structured exercise, resistance training and pain management when starting GLP‑1s but noted the findings are observational, based on selected wearable users, and require peer‑reviewed confirmation before drawing causal conclusions.